Chardan Capital Reiterates “Buy” Rating for Gain Therapeutics (NASDAQ:GANX)

Gain Therapeutics (NASDAQ:GANX)‘s stock had its “buy” rating reaffirmed by Chardan Capital in a research report issued to clients and investors on Wednesday, Benzinga reports. They currently have a $6.00 price objective on the stock. Chardan Capital’s price target suggests a potential upside of 59.15% from the company’s previous close.

Separately, HC Wainwright cut their target price on Gain Therapeutics from $10.00 to $9.00 and set a “buy” rating on the stock in a research note on Monday, December 4th.

Gain Therapeutics Trading Up 1.1 %

GANX opened at $3.77 on Wednesday. The stock has a market cap of $48.67 million, a price-to-earnings ratio of -2.20 and a beta of 0.47. The stock’s 50 day moving average price is $4.30 and its 200-day moving average price is $3.44. Gain Therapeutics has a one year low of $2.00 and a one year high of $6.19. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.30 and a current ratio of 2.30.

Institutional Trading of Gain Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. boosted its position in Gain Therapeutics by 25.8% during the 4th quarter. Vanguard Group Inc. now owns 88,385 shares of the company’s stock valued at $289,000 after acquiring an additional 18,105 shares in the last quarter. Northern Trust Corp boosted its position in shares of Gain Therapeutics by 227.7% in the 4th quarter. Northern Trust Corp now owns 43,513 shares of the company’s stock worth $142,000 after purchasing an additional 30,236 shares in the last quarter. Royal Bank of Canada boosted its position in shares of Gain Therapeutics by 947.6% in the 3rd quarter. Royal Bank of Canada now owns 210,000 shares of the company’s stock worth $689,000 after purchasing an additional 189,954 shares in the last quarter. Renaissance Technologies LLC boosted its position in shares of Gain Therapeutics by 23.0% in the 2nd quarter. Renaissance Technologies LLC now owns 47,600 shares of the company’s stock worth $213,000 after purchasing an additional 8,900 shares in the last quarter. Finally, BlackRock Inc. boosted its position in shares of Gain Therapeutics by 17.1% in the 2nd quarter. BlackRock Inc. now owns 29,024 shares of the company’s stock worth $130,000 after purchasing an additional 4,246 shares in the last quarter. Institutional investors own 11.97% of the company’s stock.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, researches and develops novel therapies to treat diseases caused by protein misfolding in Switzerland and Spain. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease.